Ebola Vaccine Passed Trials Sucessfully

The experiments held by the US National Institutes of Health showed that vaccination from Ebola virus can develop a “long-term” immunity, which can last at least for 10 months. The vaccination was successfully done on monkeys, and that means a rising prospect of successful human tests. 
Human trials started on the first week of September in the US and will continue in the UK and Africa. WHO states, that more than 2,000 people died in the West Africa during the outbreak. So these experimental treatments could help to stop the spread of Ebola.

These treatments include the vaccine developed by US National Institute of Allergy and Infectious Diseases and pharmaceutical company GlaxoSmithKline. The Ebola vaccine is supposed to trigger the immune system to develop immunity.
Director of the US National Institute of Allergy and Infectious Diseases assured that:
“The good part of this vaccine is that at five weeks or earlier you get full protection. The sobering news is the durability isn’t great, but if you give a boost, a second shot, you make it really durable”
The best proof of his words will be the good result of the vaccine when it is tried on people.  These tests will take place in the US, the University of Oxford in the UK as well as in Mali and Gambia. WHO promises to start vaccination in the West Africa by November 2014, if the vaccine is proved safe.